# MKS Inc: financial statements, quarterly

MKSI · Nasdaq · CIK 1049502 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mksi.md) · [Financials](/companies/mksi/financials.md) · [Filings](/companies/mksi/filings.md) · [Insiders](/companies/mksi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mksi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [932](/filings/0000950170-24-123394.md) | [892 d](/filings/0001193125-26-066820.md) | [868](/filings/0000950170-25-066792.md) | [887](/filings/0001193125-25-175092.md) | [896](/filings/0001193125-25-268932.md) | [934 d](/filings/0001193125-26-066820.md) | [936](/filings/0001049502-26-000062.md) | [973](/filings/0001193125-26-337821.md) | [988](/filings/0001193125-25-268932.md) | [1,033 d](/filings/0001193125-26-066820.md) | [1,078](/filings/0001049502-26-000062.md) | [1,248](/filings/0001193125-26-337821.md) |
| Cost of revenue | $m | [506](/filings/0000950170-23-061045.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [426](/filings/0000950170-24-123394.md) | [411 d](/filings/0001193125-26-066820.md) | [415](/filings/0000950170-25-066792.md) | [419](/filings/0001193125-25-175092.md) | [432](/filings/0001193125-25-268932.md) | [441 d](/filings/0001193125-26-066820.md) | [444](/filings/0001049502-26-000062.md) | [453](/filings/0001193125-26-337821.md) | [461](/filings/0001193125-25-268932.md) | [479 d](/filings/0001193125-26-066820.md) | [507](/filings/0001049502-26-000062.md) | [595](/filings/0001193125-26-337821.md) |
| Research and development | $m | [71.0](/filings/0000950170-24-123394.md) | [70.0 d](/filings/0001193125-26-066820.md) | [70.0](/filings/0000950170-25-066792.md) | [66.0](/filings/0001193125-25-175092.md) | [70.0](/filings/0001193125-25-268932.md) | [65.0 d](/filings/0001193125-26-066820.md) | [70.0](/filings/0001049502-26-000062.md) | [76.0](/filings/0001193125-26-337821.md) | [76.0](/filings/0001193125-25-268932.md) | [77.0 d](/filings/0001193125-26-066820.md) | [81.0](/filings/0001049502-26-000062.md) | [76.0](/filings/0001193125-26-337821.md) |
| Selling, general and administrative | $m | [167](/filings/0000950170-24-123394.md) | [161 d](/filings/0001193125-26-066820.md) | [170](/filings/0000950170-25-066792.md) | [161](/filings/0001193125-25-175092.md) | [167](/filings/0001193125-25-268932.md) | [176 d](/filings/0001193125-26-066820.md) | [185](/filings/0001049502-26-000062.md) | [175](/filings/0001193125-26-337821.md) | [180](/filings/0001193125-25-268932.md) | [185 d](/filings/0001193125-26-066820.md) | [190](/filings/0001049502-26-000062.md) | [200](/filings/0001193125-26-337821.md) |
| Operating income | $m | [118](/filings/0000950170-24-123394.md) | [24.0 d](/filings/0001193125-26-066820.md) | [106](/filings/0000950170-25-066792.md) | [127](/filings/0001193125-25-175092.md) | [128](/filings/0001193125-25-268932.md) | [136 d](/filings/0001193125-26-066820.md) | [111](/filings/0001049502-26-000062.md) | [135](/filings/0001193125-26-337821.md) | [138](/filings/0001193125-25-268932.md) | [143 d](/filings/0001193125-26-066820.md) | [149](/filings/0001049502-26-000062.md) | [251](/filings/0001193125-26-337821.md) |
| Interest expense | $m | [93.0](/filings/0000950170-24-123394.md) | [90.0 d](/filings/0001193125-26-066820.md) | [87.0](/filings/0000950170-25-066792.md) | [79.0](/filings/0001193125-25-175092.md) | [64.0](/filings/0001193125-25-268932.md) | [54.0 d](/filings/0001193125-26-066820.md) | [53.0](/filings/0001049502-26-000062.md) | [55.0](/filings/0001193125-26-337821.md) | [53.0](/filings/0001193125-25-268932.md) | [50.0 d](/filings/0001193125-26-066820.md) | [45.0](/filings/0001049502-26-000062.md) | [38.0](/filings/0001193125-26-337821.md) |
| Income tax | $m | [(17.0)](/filings/0000950170-24-123394.md) | [(11.0) d](/filings/0001193125-26-066820.md) | [4.0](/filings/0000950170-25-066792.md) | [(1.0)](/filings/0001193125-25-175092.md) | [(2.0)](/filings/0001193125-25-268932.md) | [(11.0) d](/filings/0001193125-26-066820.md) | [7.0](/filings/0001049502-26-000062.md) | [10.0](/filings/0001193125-26-337821.md) | [10.0](/filings/0001193125-25-268932.md) | [(18.0) d](/filings/0001193125-26-066820.md) | [18.0](/filings/0001049502-26-000062.md) | [38.0](/filings/0001193125-26-337821.md) |
| Net income | $m | [39.0](/filings/0000950170-24-123394.md) | [(69.0) d](/filings/0001193125-26-066820.md) | [15.0](/filings/0001193125-25-268932.md) | [23.0](/filings/0001193125-25-268932.md) | [62.0](/filings/0001193125-25-268932.md) | [91.0 d](/filings/0001193125-26-066820.md) | [52.0](/filings/0001193125-26-337821.md) | [62.0](/filings/0001193125-26-337821.md) | [74.0](/filings/0001193125-25-268932.md) | [107 d](/filings/0001193125-26-066820.md) | [84.0](/filings/0001193125-26-337821.md) | [175](/filings/0001193125-26-337821.md) |
| Diluted EPS | $ per share | [0.58](/filings/0000950170-24-123394.md) | not reported | [0.22](/filings/0000950170-25-066792.md) | [0.33](/filings/0001193125-25-175092.md) | [0.92](/filings/0001193125-25-268932.md) | not reported | [0.77](/filings/0001049502-26-000062.md) | [0.92](/filings/0001193125-26-337821.md) | [1.10](/filings/0001193125-25-268932.md) | not reported | [1.18](/filings/0001049502-26-000062.md) | [2.41](/filings/0001193125-26-337821.md) |
| Basic EPS | $ per share | [0.59](/filings/0000950170-24-123394.md) | not reported | [0.22](/filings/0000950170-25-066792.md) | [0.34](/filings/0001193125-25-175092.md) | [0.92](/filings/0001193125-25-268932.md) | not reported | [0.77](/filings/0001049502-26-000062.md) | [0.92](/filings/0001193125-26-337821.md) | [1.10](/filings/0001193125-25-268932.md) | not reported | [1.24](/filings/0001049502-26-000062.md) | [2.59](/filings/0001193125-26-337821.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [507](/filings/0000950170-25-026433.md) | [462](/filings/0000950170-24-057181.md) | [505](/filings/0000950170-24-093615.md) | [439](/filings/0000950170-24-123394.md) | [420](/filings/0001193125-26-066820.md) | [407](/filings/0000950170-25-066792.md) | [498](/filings/0001193125-25-175092.md) | [413](/filings/0001193125-25-268932.md) | [418](/filings/0001193125-26-337821.md) | [463](/filings/0001049502-26-000062.md) | [454](/filings/0001193125-26-337821.md) |
| Current assets | $m | [2,775](/filings/0000950170-23-061045.md) | [2,696](/filings/0000950170-25-026433.md) | [2,661](/filings/0000950170-24-057181.md) | [2,648](/filings/0000950170-24-093615.md) | [2,668](/filings/0000950170-24-123394.md) | [2,474](/filings/0001193125-26-066820.md) | [2,426](/filings/0000950170-25-066792.md) | [2,484](/filings/0001193125-25-175092.md) | [2,536](/filings/0001193125-25-268932.md) | [2,510](/filings/0001193125-26-337821.md) | [2,545](/filings/0001049502-26-000062.md) | [2,774](/filings/0001193125-26-337821.md) |
| Total assets | $m | [9,140](/filings/0000950170-23-061045.md) | [9,118](/filings/0000950170-25-026433.md) | [8,931](/filings/0000950170-24-057181.md) | [8,863](/filings/0000950170-24-093615.md) | [9,023](/filings/0000950170-24-123394.md) | [8,590](/filings/0001193125-26-066820.md) | [8,556](/filings/0000950170-25-066792.md) | [8,826](/filings/0001193125-25-175092.md) | [8,777](/filings/0001193125-25-268932.md) | [8,796](/filings/0001193125-26-337821.md) | [8,728](/filings/0001049502-26-000062.md) | [8,941](/filings/0001193125-26-337821.md) |
| Current liabilities | $m | [838](/filings/0000950170-23-061045.md) | [848](/filings/0000950170-25-026433.md) | [721](/filings/0000950170-24-057181.md) | [740](/filings/0000950170-24-093615.md) | [781](/filings/0000950170-24-123394.md) | [775](/filings/0001193125-26-066820.md) | [781](/filings/0000950170-25-066792.md) | [832](/filings/0001193125-25-175092.md) | [886](/filings/0001193125-25-268932.md) | [927](/filings/0001193125-26-337821.md) | [2,291](/filings/0001049502-26-000062.md) | [2,424](/filings/0001193125-26-337821.md) |
| Total liabilities | $m | [6,664](/filings/0000950170-23-061045.md) | [6,646](/filings/0000950170-25-026433.md) | [6,507](/filings/0000950170-24-057181.md) | [6,630](/filings/0000950170-24-093615.md) | [6,625](/filings/0000950170-24-123394.md) | [6,268](/filings/0001193125-26-066820.md) | [6,202](/filings/0000950170-25-066792.md) | [6,273](/filings/0001193125-25-175092.md) | [6,177](/filings/0001193125-25-268932.md) | [6,077](/filings/0001193125-26-337821.md) | [5,917](/filings/0001049502-26-000062.md) | [5,953](/filings/0001193125-26-337821.md) |
| Long-term debt | $m | [4,787](/filings/0000950170-23-061045.md) | [4,953](/filings/0000950170-24-021071.md) | [4,692](/filings/0000950170-24-057181.md) | [4,832](/filings/0000950170-24-093615.md) | [4,758](/filings/0000950170-24-123394.md) | [4,488](/filings/0001193125-26-066820.md) | [4,409](/filings/0000950170-25-066792.md) | [4,357](/filings/0001193125-25-175092.md) | [4,253](/filings/0001193125-25-268932.md) | [4,150](/filings/0001193125-26-337821.md) | [2,650](/filings/0001049502-26-000062.md) | [2,544](/filings/0001193125-26-337821.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [87.0](/filings/0000950170-23-061045.md) | [93.0](/filings/0000950170-25-026433.md) | [50.0](/filings/0000950170-24-057181.md) | [50.0](/filings/0000950170-24-093615.md) | [50.0](/filings/0000950170-24-123394.md) | [50.0](/filings/0001193125-26-066820.md) | [50.0](/filings/0000950170-25-066792.md) | [51.0](/filings/0001193125-25-175092.md) | [51.0](/filings/0001193125-25-268932.md) | [51.0](/filings/0001193125-26-337821.md) | [1,398](/filings/0001049502-26-000062.md) | [1,399](/filings/0001193125-26-337821.md) |
| Shareholders' equity | $m | [2,476](/filings/0000950170-24-123394.md) | [2,472](/filings/0001193125-26-066820.md) | [2,424](/filings/0001193125-25-268932.md) | [2,233](/filings/0001193125-25-268932.md) | [2,398](/filings/0001193125-25-268932.md) | [2,322](/filings/0001193125-26-337821.md) | [2,354](/filings/0001193125-26-337821.md) | [2,553](/filings/0001193125-26-337821.md) | [2,600](/filings/0001193125-25-268932.md) | [2,719](/filings/0001193125-26-337821.md) | [2,811](/filings/0001193125-26-337821.md) | [2,988](/filings/0001193125-26-337821.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [160 d](/filings/0000950170-24-123394.md) | [181 d](/filings/0001193125-26-066820.md) | [67.0](/filings/0000950170-25-066792.md) | [122 d](/filings/0001193125-25-175092.md) | [163 d](/filings/0001193125-25-268932.md) | [176 d](/filings/0001193125-26-066820.md) | [141](/filings/0001049502-26-000062.md) | [165 d](/filings/0001193125-26-337821.md) | [197 d](/filings/0001193125-25-268932.md) | [142 d](/filings/0001193125-26-066820.md) | [53.0](/filings/0001049502-26-000062.md) | [243 d](/filings/0001193125-26-337821.md) |
| Capital expenditure | $m | [18.0 d](/filings/0000950170-24-123394.md) | [34.0 d](/filings/0001193125-26-066820.md) | [18.0](/filings/0000950170-25-066792.md) | [27.0 d](/filings/0001193125-25-175092.md) | [22.0 d](/filings/0001193125-25-268932.md) | [51.0 d](/filings/0001193125-26-066820.md) | [18.0](/filings/0001049502-26-000062.md) | [29.0 d](/filings/0001193125-26-337821.md) | [51.0 d](/filings/0001193125-25-268932.md) | [50.0 d](/filings/0001193125-26-066820.md) | [25.0](/filings/0001049502-26-000062.md) | [54.0 d](/filings/0001193125-26-337821.md) |
| Dividends paid | $m | [15.0 d](/filings/0000950170-24-123394.md) | [15.0 d](/filings/0001193125-26-066820.md) | [15.0](/filings/0000950170-25-066792.md) | [15.0 d](/filings/0001193125-25-175092.md) | [14.0 d](/filings/0001193125-25-268932.md) | [15.0 d](/filings/0001193125-26-066820.md) | [15.0](/filings/0001049502-26-000062.md) | [15.0 d](/filings/0001193125-26-337821.md) | [14.0 d](/filings/0001193125-25-268932.md) | [15.0 d](/filings/0001193125-26-066820.md) | [17.0](/filings/0001049502-26-000062.md) | [17.0 d](/filings/0001193125-26-337821.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0000950170-25-066792.md) | [0.0 d](/filings/0001193125-25-175092.md) | [0.0 d](/filings/0001193125-25-268932.md) | [0.0 d](/filings/0001193125-26-066820.md) | [45.0](/filings/0001049502-26-000062.md) | [0.0 d](/filings/0001193125-26-337821.md) | [0.0 d](/filings/0001193125-25-268932.md) | [0.0 d](/filings/0001193125-26-066820.md) | [0.0](/filings/0001049502-26-000062.md) | [0.0 d](/filings/0001193125-26-337821.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [61.1](/filings/0000950170-23-061045.md) | [66.7](/filings/0000950170-24-057181.md) | [66.8](/filings/0000950170-24-093615.md) | [67.1](/filings/0000950170-24-123394.md) | [67.4](/filings/0000950170-25-066792.md) | [67.5](/filings/0001193125-25-175092.md) | [67.6](/filings/0001193125-25-268932.md) | [67.7](/filings/0001049502-26-000062.md) | [67.4](/filings/0001193125-26-337821.md) | [67.6](/filings/0001193125-25-268932.md) | [71.1](/filings/0001049502-26-000062.md) | [72.7](/filings/0001193125-26-337821.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 67,617,558 at 2026-07-28, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337821.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.